Verona Details COPD Opportunity For Ensifentrine
ENHANCE Program Start Will Be Subject To Extra Funding
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.
